Foghorn Therapeutics Inc.
Foghorn Therapeutics is a clinical-stage biotechnology company developing precision medicines that target the chromatin regulatory system to address abnormal gene expression. Its Gene Traffic Control platform combines genomic and epigenomic tools, screening technology and medicinal chemistry to identify and develop drug candidates. Foghorn works on more than seven programs, including inhibitors, protein degraders and transcription factor disruptors, with targets such as SMARCA2, CBP, EP300 and ARID1B. Its most advanced candidate, FHD-909, is a selective SMARCA2 inhibitor in a Phase 1 trial for cancers including non-small cell lung cancer. Foghorn develops its pipeline for genetically defined patient populations, initially focusing on oncology while also applying its platform to other disease areas. It collaborates with Eli Lilly on SMARCA2 and other oncology programs, including co-development and co-commercialization of the selective SMARCA2 program in the United States. The company is headquartered in Cambridge, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $FHTX in the last 30 days.
See all $FHTX insider activity →Foghorn Therapeutics reported $156M in cash and equivalents, with runway into H2 2029. The company targets first-in-human trials for its IBD program by end-2027 and an IND for its EP300 degrader in 2027.
Foghorn Therapeutics reported 3Q 2026 revenue of $83.54M, up year-over-year, due to a $74.1M adjustment from its Lilly collaboration. EPS was $0.8. The company cut 40% of its workforce to focus on proprietary programs, with completion expected in Q4 2026. R&D expenses fell to $18.8M.
Foghorn Therapeutics Inc. (FHTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update - Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027 - Selective EP300 degrader with potential to trea
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning FHTX (Foghorn Therapeutics Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 1 bearish.
Recent FHTX coverage spans financial news and earnings.
Positive liquidity outlook may support share price stability or modest upside.
Earnings beat on revenue but collaboration with Lilly halted and large layoffs suggest near‑term pressure.
Strong cash position and revenue growth may support near‑term upside, but no immediate catalyst.
Trial failure and downgrade create immediate sell pressure on FHTX.
The termination of the Phase 1 program and partnership signals reduced future revenue potential and increased execution risk.
AlphAI scores every news story that mentions FHTX with an AI model for sentiment and relevance, and aggregates insider trades from Foghorn Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Foghorn Therapeutics reported $156M in cash and equivalents, with runway into H2 2029. The company targets first-in-human trials for its IBD program by end-2027 and an IND for its EP300 degrader in 2027.
Foghorn Therapeutics reported 3Q 2026 revenue of $83.54M, up year-over-year, due to a $74.1M adjustment from its Lilly collaboration. EPS was $0.8. The company cut 40% of its workforce to focus on proprietary programs, with completion expected in Q4 2026. R&D expenses fell to $18.8M.
Foghorn Therapeutics Inc. (FHTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update - Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027 - Selective EP300 degrader with potential to trea
Evercore ISI downgraded Foghorn Therapeutics (FHTX) to In Line from Outperform, cutting its price target to $3.00 from $14.00 after the discontinuation of its lead clinical program, FHD-909. The stock is down 64% year-to-date, trading at $1.95. The firm removed FHD-909 from its model, reduced operating expenses, and estimates $131 million in net cash by year-end 2026. Other analysts have also adjusted their ratings and price targets following the drug program's halt.
Foghorn Therapeutics (FHTX) will halt development of FHD-909 after Phase 1 trial results showed insufficient efficacy, ending collaboration with Eli Lilly. The company will focus on its proprietary pipeline and reduce workforce by 40%. Wedbush downgraded FHTX to Neutral, cutting its price target to $2. FHTX shares closed at $2.02, down 30.82%.
Analysts this week focused on valuation discipline, trimming winners and cutting stalled growth stories. Key moves: Wells Fargo downgraded FS KKR (FSK) to Underweight with a $10 target, citing credit risks. Stifel upgraded STAAR Surgical (STAA) to Buy, raising its target to $31. Deutsche Bank downgraded Commerzbank (CBKG) to Hold. Citizens downgraded Foghorn Therapeutics (FHTX) after a drug trial failure. UBS downgraded Gurit Holding (GURN) to Neutral.
Analysts updated price targets for several companies. Argus raised Accenture's target to $260, Susquehanna cut CSX's to $55, and Rothschild upgraded Abbott Labs to Buy with a $127 target. Other notable changes include Synaptics, Nike, AtriCure, McCormick, Foghorn, Marathon, and Shattuck Labs.
Analysts downgraded several companies: Foghorn Therapeutics (FHTX) to Neutral, First Busey (BUSE) to Neutral with a $30 target, AST SpaceMobile (ASTS) to Neutral with a $65 target, AtriCure (ATRC) to Hold with a $57 target, and Equity Bancshares (EQBK) to Neutral with a $52 target. ASTS closed at $57.04 on Thursday.
Citizens downgraded Foghorn Therapeutics (FHTX) to Market Perform after it and Eli Lilly discontinued the FHD-909 drug candidate due to poor efficacy. Shares fell 18% to $2.88, extending a 34% YTD decline. Citizens cited lack of near-term catalysts, noting shares trade at a 26% premium to cash reserves. InvestingPro analysis suggests undervaluation, while Stifel lowered its price target to $5.00 but maintained a Buy rating.
Stifel reduced Foghorn Therapeutics' (FHTX) price target to $5.00 from $12.00, citing pipeline shifts. FHTX shares trade at $2.70, down 34% YTD. The company will focus on its wholly owned pipeline, extending cash runway to mid-2029. Stifel values FHTX at $138M net cash by 2026. Citizens reiterated a Market Outperform rating with a $9.00 target.
